SLCO1B1 单核苷酸多态性对普伐他汀药效学的影响。
The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.
机构信息
Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, The Royal Free and University College London Medical School, London, UK.
出版信息
Br J Clin Pharmacol. 2012 Feb;73(2):303-6. doi: 10.1111/j.1365-2125.2011.04090.x.
Abstract
AIM
To determine whether the SNP rs4149056 in SLCO1B1 alters the pharmacodynamics of pravastatin.
METHODS
rs4149056 was genotyped in 626 pravastatin-treated participants in the WOSCOPS trial and the response after 1 year of treatment was compared between the different genotypes.
RESULTS
Pravastatin reduced serum LDL cholesterol by 22.2% in TT homozygotes, by 22.2% in TC heterozygotes and by 17.7% in CC homozygotes (TT + TC vs. CC P value 0.33). There were no significant differences in the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin between the genotypes.
CONCLUSION
The rs4149056 SNP did not significantly affect the pharmacodynamics of pravastatin.
摘要
目的
确定 SLCO1B1 中的 SNP rs4149056 是否改变普伐他汀的药效学。
方法
在 WOSCOPS 试验中对 626 名接受普伐他汀治疗的参与者进行了 rs4149056 基因分型，并比较了不同基因型在 1 年治疗后的反应。
结果
TT 纯合子中普伐他汀降低血清 LDL 胆固醇 22.2%，TC 杂合子中降低 22.2%，CC 纯合子中降低 17.7%（TT+TC 与 CC 相比，P 值为 0.33）。不同基因型的总胆固醇、LDL、HDL、甘油三酯或 CRP 对普伐他汀的反应无显著差异。
结论
rs4149056 SNP 对普伐他汀的药效学没有显著影响。
相似文献
1
The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.SLCO1B1 单核苷酸多态性对普伐他汀药效学的影响。
Br J Clin Pharmacol. 2012 Feb;73(2):303-6. doi: 10.1111/j.1365-2125.2011.04090.x.
2
Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.SLCO1B1 基因座的遗传变异与老年人普伐他汀降低低密度脂蛋白胆固醇的反应。
Atherosclerosis. 2012 Feb;220(2):413-7. doi: 10.1016/j.atherosclerosis.2011.09.028. Epub 2011 Sep 21.
3
SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.SLCO1B1基因521T→C功能型基因多态性与多次服用普伐他汀对中国冠心病患者的降脂疗效
Br J Clin Pharmacol. 2007 Sep;64(3):346-52. doi: 10.1111/j.1365-2125.2007.02892.x. Epub 2007 Apr 18.
4
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.普伐他汀对胆固醇合成的急性影响与SLCO1B1（编码OATP1B1）单倍型*17相关。
Pharmacogenet Genomics. 2005 May;15(5):303-9. doi: 10.1097/01213011-200505000-00005.
5
Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy.
J Hum Genet. 2006;51(9):822-826. doi: 10.1007/s10038-006-0025-1. Epub 2006 Aug 18.
6
Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.多药耐药基因 1 和溶质载体有机阴离子转运多肽 1B1 多态性是否影响阿托伐他汀的治疗反应？一项针对埃及高胆固醇血症患者队列的研究。
Mol Diagn Ther. 2013 Oct;17(5):299-309. doi: 10.1007/s40291-013-0038-3.
7
Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels.SLCO1B1*1b和*5单倍型对普伐他汀降低胆固醇能力及基础甾醇血清水平的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2006 Apr;373(1):45-50. doi: 10.1007/s00210-006-0053-6. Epub 2006 Mar 28.
8
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.SLCO1B1基因多态性对多剂量普伐他汀药代动力学及降脂疗效的影响。
Clin Pharmacol Ther. 2006 May;79(5):419-26. doi: 10.1016/j.clpt.2006.01.010. Epub 2006 Apr 11.
9
Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.SLCO1B1 多态性与阿托伐他汀和辛伐他汀在中国人群中降脂作用的相关性研究。
Eur J Clin Pharmacol. 2013 Jun;69(6):1269-74. doi: 10.1007/s00228-012-1453-9. Epub 2012 Dec 22.
10
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.SLCO1B1基因多态性和性别影响普伐他汀的药代动力学，但不影响氟伐他汀的药代动力学。
Clin Pharmacol Ther. 2006 Oct;80(4):356-66. doi: 10.1016/j.clpt.2006.06.010.
引用本文的文献
1
PharmVar GeneFocus: SLCO1B1.药物代谢基因变异体数据库：SLCO1B1。
Clin Pharmacol Ther. 2023 Apr;113(4):782-793. doi: 10.1002/cpt.2705. Epub 2022 Jul 27.
2
Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.普伐他汀异构体对 OATP1B1 介导的转运的功能影响。
Drug Metab Dispos. 2020 Nov;48(11):1192-1198. doi: 10.1124/dmd.120.000122. Epub 2020 Sep 5.
3
Genomics and Precision Medicine to Direct Statin Use in the Young.基因组学与精准医学指导年轻人使用他汀类药物
Prog Pediatr Cardiol. 2009 Sep;54. doi: 10.1016/j.ppedcard.2019.101145. Epub 2019 Aug 27.
4
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.SLCO1B1 基因变异对儿科高胆固醇血症患者中瑞舒伐他汀系统暴露的影响。
Clin Transl Sci. 2020 May;13(3):628-637. doi: 10.1111/cts.12749. Epub 2020 Mar 9.
5
Genetic contribution to lipid target achievement with statin therapy: a prospective study.他汀类药物治疗的血脂目标达成的遗传贡献：一项前瞻性研究。
Pharmacogenomics J. 2020 Jun;20(3):494-504. doi: 10.1038/s41397-019-0136-7. Epub 2019 Dec 6.
6
Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.支持在随机对照试验中纳入药物遗传生物标志物的证据。
J Pers Med. 2019 Sep 1;9(3):42. doi: 10.3390/jpm9030042.
7
Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia.6种基因变异对血脂异常患者他汀类药物疗效的影响。
J Clin Lab Anal. 2018 Oct;32(8):e22566. doi: 10.1002/jcla.22566. Epub 2018 May 7.
8
Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver.用人类大脑和肝脏的全转录组测序检测编码膜转运体的 mRNA 转录本的表达。
Pharmacogenet Genomics. 2013 May;23(5):269-78. doi: 10.1097/FPC.0b013e32835ff536.
9
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.高密度脂蛋白胆固醇升高疗法的药物基因组学
Expert Rev Cardiovasc Ther. 2013 Mar;11(3):355-64. doi: 10.1586/erc.12.134.
本文引用的文献
1
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.SLCO1B1（OATP1B1）基因多态性对他汀类药物治疗反应的影响。
Pharmacogenomics J. 2010 Feb;10(1):1-11. doi: 10.1038/tpj.2009.54. Epub 2009 Nov 3.
2
Impact of OATP transporters on pharmacokinetics.有机阴离子转运多肽（OATP）转运体对药代动力学的影响。
Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Epub 2009 Sep 25.
3
Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.基于生理的药代动力学建模以预测普伐他汀在人体内由转运体介导的清除率和分布情况。
J Pharmacol Exp Ther. 2009 Feb;328(2):652-62. doi: 10.1124/jpet.108.146647. Epub 2008 Nov 10.
4
SLCO1B1 variants and statin-induced myopathy--a genomewide study.溶质载体有机阴离子转运体家族1成员B1（SLCO1B1）变异与他汀类药物诱发的肌病——一项全基因组研究
N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.
5
SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.SLCO1B1基因521T→C功能型基因多态性与多次服用普伐他汀对中国冠心病患者的降脂疗效
Br J Clin Pharmacol. 2007 Sep;64(3):346-52. doi: 10.1111/j.1365-2125.2007.02892.x. Epub 2007 Apr 18.
6
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.SLCO1B1基因多态性显著影响辛伐他汀酸的药代动力学。
Pharmacogenet Genomics. 2006 Dec;16(12):873-9. doi: 10.1097/01.fpc.0000230416.82349.90.
7
Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy.
J Hum Genet. 2006;51(9):822-826. doi: 10.1007/s10038-006-0025-1. Epub 2006 Aug 18.
8
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.SLCO1B1基因多态性对多剂量普伐他汀药代动力学及降脂疗效的影响。
Clin Pharmacol Ther. 2006 May;79(5):419-26. doi: 10.1016/j.clpt.2006.01.010. Epub 2006 Apr 11.
9
Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study.在WOSCOPS研究中，凝血因子XII 46C>T基因多态性与冠心病（CHD）风险的关联。
Atherosclerosis. 2002 Nov;165(1):153-8. doi: 10.1016/s0021-9150(02)00196-x.
10
Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).白细胞介素-6 -174G>C基因多态性与苏格兰西部冠心病预防研究（WOSCOPS）中的冠心病风险
Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):599-604. doi: 10.1161/01.atv.0000013283.84306.1a.
Zotero 插件